ABBISKO-B(02256.HK): Positive Preliminary Phase II Data of ABSK061 Plus ABSK043 for FGFR2-Positive Advanced Gastric Cancer Released
NewTimeSpace News: Abbisko Cayman Limited (02256.HK) announced that its subsidiary Abbisko Therapeutics presented preliminary results from a Phase II clinical study evaluating its independently developed oral highly selective FGFR2/3 inhibitor ABSK061 combined with oral PD-L1 inhibitor ABSK043, with or without CAPOX chemotherapy, in patients with FGFR2-positive advanced gastric cancer and gastroesophageal junction cancer (GC/GEJC) at the 2026 ASCO Annual Meeting. The data demonstrated favourable safety profiles and promising anti-tumour activity for the combination regimen.
NewTimeSpace News: Abbisko Cayman Limited (02256.HK) issued a voluntary announcement on 26 June 2026, disclosing that its subsidiary Shanghai Abbisko Therapeutics released Phase II study results of ABSK061 in combination with ABSK043 at the 2026 ASCO Annual Meeting.
As disclosed in the announcement, the Company unveiled preliminary clinical data from a Phase II trial assessing ABSK061 (an oral, highly selective FGFR2/3 inhibitor discovered in-house) combined with oral PD-L1 inhibitor ABSK043, with or without CAPOX (capecitabine plus oxaliplatin) chemotherapy, for the treatment of FGFR2-positive advanced gastric cancer and gastroesophageal junction cancer.
Trial data showed that ABSK061 plus ABSK043 (with or without CAPOX) delivered well-tolerated safety profiles and robust anti-tumour activity in patients with FGFR2-positive advanced GC/GEJC, highlighting the therapeutic potential of targeted therapy combined with immunotherapy as a novel treatment option for this patient population.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- ABBISKO-B(02256.HK): Enters Strategic Research Collaboration and License Agreement with Eli Lilly, Total Potential Deal Value Up to USD1.9 Billion
- ABBISKO-B (02256.HK) plans to issue in total 42.9 million shares by placement, with estimated net proceeds of HKD 517.3 million
- Heng Pharmaceutical-B (02256.HK) Presents Novel Combination Modelling Framework for ABSK-011 at PAGE Conference
